Gallbladder Neoplasms
11
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Agnostic Therapy in Rare Solid Tumors
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Selective Rather Than Routine Histopathological Examination Following Appendectomy and Cholecystectomy
Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer
EEG Parameters Between Remimazolam- and Propofol-based Anesthesia
Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms
Chinese Research Group of Gallbladder Cancer
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma